17 November 2026
by Jeff Craven

Recon: FDA approves Roche’s oral SERD for late-stage breast cancer; Lilly strikes up to $5.9B cancer deal with Stipple Bio

Recon-RF-Dept-380x215.png

Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.

In Focus: US

  • FDA approves new breast cancer drug, providing new option for some patients, boost for Roche (STAT) (Endpoints)
  • FDA proposes to withdraw approval for Salerno's cholesterol medication (Reuters)
  • Roche’s Gazyva adds 3rd immune indication with first FDA nod for primary membranous nephropathy (Fierce Pharma)
  • In a win for MAHA, FDA creates new regulatory category for the supplement NAC (STAT)
  • FDA signals more adcomms ahead for contested rare disease applications (Pink Sheet)
  • FDA sees generics, not compounding, as answer to GLP-1 costs (Pink Sheet)
  • Sponsors will see ‘super intelligence’ on FDA forms, webpages soon, but using ‘AI’ still OK (Pink Sheet)
  • Fixing Humpty Dumpty - building a better approach to personnel management at the FDA (Rob Califf)

In Focus: International

  • Sobi’s Tryngolza approved in the EU for severe hypertriglyceridemia (The Pharma Letter)
  • Incyte says EU approves oral treatment for chronic skin disease (Reuters)
  • Korea rare disease pilot scheme selects initial drugs (Pink Sheet)
  • More time without competition: Australia extends market exclusivity to 3 years (Pink Sheet)
  • EU’s mandatory drug repurposing power raises liability concerns (Pink Sheet)
  • Congo's Ebola outbreak is spreading and killing at a record pace (Reuters)
  • Gilead signs generic licensing deals for experimental Ebola drug (Reuters)
  • Australia's Mayne Pharma jumps to 1-year high on $408 million Gedeon Richter takeover (Reuters)

Pharma & Biotech

  • Lilly strikes up to $5.9B cancer deal with Stipple Bio (Endpoints) (Reuters)
  • PhRMA’s new CEO Cantor restructures leadership team, eliminating public affairs role (Pink Sheet)
  • Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial (STAT) (Reuters)
  • Rhythm drug shows sustained weight reduction in patients with brain damage-related obesity (Reuters)
  • AriBio’s repurposed erectile dysfunction drug for Alzheimer’s yields tepid results (Endpoints) (BioSpace)
  • Priavoid’s amyloid-detangling pill fails to meaningfully slow disease in phase 2 Alzheimer’s study (Endpoints)
  • Oncoinvent reports Radspherin data in ovarian cancer (The Pharma Letter)
  • AI drug developer Isomorphic raises $5 billion in Series C round (Reuters)
  • Marrow raises $173M for siRNA drug to compete with one-time CRISPR therapy for sickle cell (Endpoints) (STAT)
  • AstraZeneca, Alexion's myasthenia gravis treatment enters crowded market (Endpoints)

Medtech

  • MiniMed gets FDA nod for tubeless insulin pump (MedTech Dive)
  • Tandem wins FDA clearance for tubeless automated insulin delivery system (MedTech Dive)
  • Medtronic to buy Contego Medical for $380M (MedTech Dive)
  • Patient data startup b.well launches tools to make AI chatbots safer (Endpoints)

Food & Nutrition

  • Study finds genetic links between drug-resistant foodborne pathogens in humans, foods, animals (Food Safety Magazine)
  • Countries try to solve food safety trade disputes at WTO meeting (Food Safety News )

Government & Legal

  • Opinion: Fixing Humpty Dumpty (Rob Califf)
  • NIAID acting head John Powers III appointed as the permanent director (STAT) (New York Times)
  • Georgia, Kansas and Texas eye Medicaid expansion after midterms romp (Politico)
  • New Trump regulation promises to crush ‘fraudsters.’ All the savings come from Medicare Advantage (STAT)
  • Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs (STAT)
  • US must intensify vaccination effort to regain measles-free status lost after 26 years (Reuters)

Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, biopharma and medtech news stories from around the globe. Regulatory Recon is published each week on Monday, Tuesday and Thursday.

A story’s inclusion in Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.